SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001213900-22-054293
Filing Date
2022-09-06
Accepted
2022-09-06 17:21:24
Documents
14
Period of Report
2022-08-31
Items
Item 1.03: Bankruptcy or Receivership
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea165390-8k_clarusthera.htm   iXBRL 8-K 35819
2 PRESS RELEASE DATED SEPTEMBER 5, 2022. ea165390ex99-1_clarusthera.htm EX-99.1 12024
3 GRAPHIC image_001.jpg GRAPHIC 3694
  Complete submission text file 0001213900-22-054293.txt   233064

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE crxt-20220831.xsd EX-101.SCH 3339
5 XBRL LABEL FILE crxt-20220831_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE crxt-20220831_pre.xml EX-101.PRE 22395
8 EXTRACTED XBRL INSTANCE DOCUMENT ea165390-8k_clarusthera_htm.xml XML 3496
Mailing Address 555 SKOKIE BOULEVARD, SUITE 340 NORTHBROOK IL 60062
Business Address 555 SKOKIE BOULEVARD, SUITE 340 NORTHBROOK IL 60062 (847) 562-4300
Clarus Therapeutics Holdings, Inc. (Filer) CIK: 0001817944 (see all company filings)

IRS No.: 851231852 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39802 | Film No.: 221229109
SIC: 2836 Biological Products, (No Diagnostic Substances)